Bristol Myers sues the federal government over 340B, following other drugmakers
Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model for distributing 340B drug discounts. Under the drugmaker's plan, hospitals...
View ArticleRecursion reduces workforce; Oxford Nanopore teams up with UK Biobank
Plus, news about Portage Biotech: Recursion’s layoffs: After merging with fellow AI-driven biotech Exscientia this fall, Recursion Pharmaceuticals laid off less than 20% of the combined company, a...
View ArticleOutlook's shares crash as wet AMD drug flunks Phase 3 test
After the FDA rejected Outlook Therapeutics’ ophthalmic formulation of bevacizumab last year, the experimental therapy has now failed a late-stage study in patients with a degenerative eye disease. In...
View ArticleAdvanz Pharma faces revocation of European authorization for liver disease...
The conditional marketing authorization for Advanz Pharma’s liver disease treatment Ocaliva has been revoked following a decision by the General Court of the European Union, the company announced...
View ArticleNovartis to cut 139 jobs in NJ as part of commercial refocus
Novartis is laying off 139 employees in East Hanover, NJ, as the company shifts its commercial resources away from two “well-established” medicines. The layoffs will mainly affect members of the...
View ArticleFDA is looking into hematology risks after patients take Bluebird's Skysona...
The FDA said Wednesday that it is investigating "serious risk of hematologic malignancy" following the administration of bluebird bio's Skysona, a gene therapy approved for the rare disease known as...
View ArticleApplied Therapeutics' rare disease drug gets a CRL
The FDA rejected Applied Therapeutics’ experimental treatment for a rare disease called classic galactosemia, citing deficiencies with the application. The company, while “disappointed with the FDA’s...
View ArticleRelmada's rapid-acting NMDA depression drug expected to fail second Phase 3
Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to fail, cratering its stock price. The study’s data monitoring committee said...
View ArticleAstraZeneca's new EVP of international amid China investigation; Janux’s...
Plus, news about Arrakis, Eli Lilly, Everest Medicines, Teva, Rondo Therapeutics, Trevi Therapeutics, Foresee Pharmaceuticals and Revolution Medicines: AstraZeneca taps new leader to run China...
View ArticleNovavax sells Czech facility to Novo Nordisk for $200M to cut costs
Novo Nordisk is buying a vaccine manufacturing factory from Novavax for $200 million to expand production of its current and future mammalian-based products, a spokesperson for the Danish drugmaker...
View ArticleSickle cell gene therapies included in new Medicaid access model
The Biden Administration said Wednesday that it has secured agreements with Vertex Pharmaceuticals and bluebird bio for their sickle cell disease gene therapies to be the first in a new access model...
View ArticleTrade group tells FDA that semaglutide is not too 'complex' for compounding
The Alliance for Pharmacy Compounding told the FDA last week that Novo Nordisk's weight loss medicine semaglutide is not too difficult to compound, pushing back against the Danish pharma's arguments...
View ArticleModerna defends pandemic prep as vaccine skeptics gain power
Moderna CEO Stéphane Bancel argued that the drug industry's efforts to prepare for a future pandemic are meant to protect Americans, defending the sector's work even as President-elect Donald Trump...
View ArticleNovo Nordisk budgets $409M for new quality control lab in Denmark
Novo Nordisk is spending DKK 2.9 billion ($409 million) to build a new quality control laboratory and will move existing operations into the site to create a “central hub.” The new 53,000-square meter...
View ArticleGSK, Zhifei extend shingles vaccine pact for less money
In a week of back-to-back new deals, GSK is extending its Shingrix agreement in China and adding a collaboration for its RSV vaccine Arexvy. But the changes mean the UK pharma could get millions of ...
View ArticleCG Oncology’s bladder cancer treatment shows durability potential in Phase 3
CG Oncology says its immunotherapy candidate that could help patients avoid surgery may deliver lasting responses in a certain form of bladder cancer based on late-stage trial data. The California...
View ArticleNuvig raises $161M as it prepares for Phase 2 study in hot autoimmune field
An immunomodulatory startup called Nuvig Therapeutics announced a $161 million Series B amid rising competition to develop new and better autoimmune medicines. Nuvig, based in Menlo Park, CA, is...
View ArticleGSK's third new pact of the week focuses on Alzheimer's with startup Muna...
GSK's BD team was busy leading up to the Thanksgiving holiday. In the last two days, the UK-based pharma has announced three new partnerships on top of
View ArticleUK to limit access to Lilly’s Zepbound; VivaVision’s positive Phase 2
Plus, news about Atlas Venture: NICE plans a limited rollout of Eli Lilly’s Zepbound: The UK’s drug price watchdog confirmed its prior recommendation for the weight loss drug, but it plans to ...
View Article